Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
27 June 2019Website:
http://bridgebio.comNext earnings report:
21 February 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 22 Nov 2024 21:05:58 GMTDividend
Analysts recommendations
Institutional Ownership
BBIO Latest News
BridgeBio announced the FDA approval of Attruby (acoramidis) for the treatment of patients with ATTR-CM. The label looks clean and it includes all the relevant clinical data. Attruby's approval also triggers a $500 million milestone payment to BridgeBio under the royalty-backed deal it signed earlier this year and removes a regulatory and funding overhang on the stock.
The U.S. Food and Drug Administration has approved BridgeBio's drug for a rare and deadly heart condition, the company said on Friday, making it the first new treatment in a market dominated by Pfizer's blockbuster Vyndaqel.
- Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR. Attruby has been shown to preserve the native function of TTR as a transport protein of thyroxine and vitamin A and to demonstrate benefit on cardiovascular outcomes
- In Cohort 5 of PROPEL 2, daily oral treatment of infigratinib at 0.25mg/kg resulted in statistically significant and sustained increases in annualized height velocity (AHV), with a mean change from baseline of +2.50cm/year at Month 18 (P=0.001)
- Case study co-authored by members of BridgeBio senior management and BridgeBio co-founder and MIT professor, Andrew W. Lo, Ph.D.
Upcoming Food and Drug Administration decisions could push these stocks through the roof.
PALO ALTO, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, announced today that outcomes data through 42 months from the ongoing long-term open-label extension of ATTRibute-CM, its Phase 3 study of acoramidis in ATTR-CM, will be shared in a featured science oral presentation at the American Heart Association (AHA) Scientific Sessions, taking place in Chicago, Illinois on November 16 – 18, 2024. In addition to the presentation, BridgeBio was selected to share three posters in moderated poster sessions on ATTR-CM.
- Acoramidis treatment led to a highly significant reduction in all-cause mortality (ACM) and recurrent cardiovascular-related hospitalizations (CVH) at Month 30 compared with placebo
Investors are optimistic that small- and mid-cap stocks will rally this year after a tough 2023, as attention shifts from the AI-focused Magnificent Seven.
- Breakthrough Therapy Designation was granted based on preliminary clinical evidence from the PROPEL 2 clinical trial, meeting the FDA's requirement of potentially demonstrating substantial improvement in efficacy over available therapies on clinically significant endpoint(s)
What type of business is BridgeBio Pharma?
BridgeBio Pharma, Inc. is a pharmaceutical company engaged in research and development of various drugs for genetic diseases. The company was founded in 2015, with its headquarters located in Palo Alto, California. BridgeBio Pharma's portfolio includes about 20 development programs for various products at different stages of development. The company's main candidates are: BBP-265, an oral low-molecular-weight transthyretin (TTR) intended for the treatment of transthyretin amyloidosis. Infigratinib, an oral selective FGFR1-3 tyrosine kinase inhibitor for the treatment of FGFR-driven cancer and achondroplasia. BBP-631, a preclinical gene transfer candidate product for the treatment of congenital adrenal hyperplasia (CAH) caused by 21OHD. BBP-454, a preclinical research program focused on new approaches to inhibiting KRAS for cancer treatment.
What sector is BridgeBio Pharma in?
BridgeBio Pharma is in the Healthcare sector
What industry is BridgeBio Pharma in?
BridgeBio Pharma is in the Biotechnology industry
What country is BridgeBio Pharma from?
BridgeBio Pharma is headquartered in United States
When did BridgeBio Pharma go public?
BridgeBio Pharma initial public offering (IPO) was on 27 June 2019
What is BridgeBio Pharma website?
https://bridgebio.com
Is BridgeBio Pharma in the S&P 500?
No, BridgeBio Pharma is not included in the S&P 500 index
Is BridgeBio Pharma in the NASDAQ 100?
No, BridgeBio Pharma is not included in the NASDAQ 100 index
Is BridgeBio Pharma in the Dow Jones?
No, BridgeBio Pharma is not included in the Dow Jones index
When was BridgeBio Pharma the previous earnings report?
No data
When does BridgeBio Pharma earnings report?
The next expected earnings date for BridgeBio Pharma is 21 February 2025